Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Expands Agios Collaboration In Cancer Metabolism

This article was originally published in The Pink Sheet Daily

Executive Summary

Cancer metabolism specialist Agios extends research collaboration with Celgene, picking up an additional $20 million.

You may also be interested in...



How To Place Bets On Early Oncology Assets

With late-stage assets scarce, Campbell Alliance consultants offer tips for spotting early oncology opportunities, as part of Windhover’s Therapeutic Area Partnerships annual showcase of top unpartnered assets. MEI Pharma, Macrogenics and EnGeneIC are among the companies featured this year.

Agios Opens Doors To Other Investors, Expands Into Genetic Disorders

Agios brings in a $78 million in financing from both previous venture investors and new public investor funds, as it embarks on research of rare diseases caused by an inborn error of metabolism.

Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?

The same advances in scientific understanding of the molecular basis of cancer that have propelled the rise of targeted oncologics also hold out the tantalizing prospect of expanded chemoprevention in cancer, the American Association for Cancer Research suggests in its Cancer Progress Report 2011.

Related Content

Topics

UsernamePublicRestriction

Register

PS072986

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel